EDEMA2:EVALUATION OF DX-88'S EFFECTS IN MITIGATING ANGIOEDEMA, AN OPEN LABEL STD

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。主要目的：这是一项开放标签研究，旨在评估在遗传性血管水肿（HAE）患者中重复给药DX-88的安全性和有效性。 主要终点是：>成功结局的比例，即，在单次给药后4小时开始发作消退，并在单次给药后维持超过24小时。 >有部分反应的患者比例，即对输注的初始反应，然后在输注后4 - 24小时复发。 > Sa

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives: This is an open label study designed to assess the safety and effectiveness of repeated dosing of DX-88 in patients with hereditary angeoedema (HAE). Primary endpoints are: >The proportion of successful outcomes i.e., attack resolution begun by four hours after a single dose and maintained for greater than 24 hours after a single dose. > The proportion of patients who have a partial response, that is an initial response to the infusion followed by a relapse 4 - 24 hours after the infustion. > Sa